Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia

There is great interest in identifying a glucagon-like peptide-1 (GLP-1)–based combination therapy that will more effectively promote weight loss in patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) is a compelling yet previously unexplored drug candidate to combine with GLP-1 due t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Adv
Autori principali: Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D'Alessio, D. A., Campbell, J. E., Chilkoti, A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Association for the Advancement of Science 2020
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449677/
https://ncbi.nlm.nih.gov/pubmed/32923621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaz9890
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi